Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

Wednesday, September 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: United Therapeutics Corporation has successfully prevailed in a patent litigation case against Liquidia Technologies, with the U.S. District Court for Delaware ruling that Liquidia infringed on two of United Therapeutics' patents. The patents pertain to the use of inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease. This ruling reinforces United Therapeutics' intellectual property rights in this area.

Market Sentiment Analysis

POSITIVE FACTORS

  • United Therapeutics wins patent litigation against Liquidia.
  • Court ruling supports the use of inhaled treprostinil.
  • Affirms United Therapeutics' intellectual property rights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+83%
120-day peak, hindsight
Typical move
6.5%
average across 6 past catalysts
Lead asset
GGTA1 KO Thymokidney
Phase 1 · ESRD (End-Stage Renal Disease)

Full Press Release Details

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).“We are pleased with the Co

Frequently Asked Questions

What was the outcome of the patent litigation?

The court ruled in favor of United Therapeutics, finding Liquidia infringed on its patents.

What does the patent cover?

The patent covers the use of inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease.

Which court issued the ruling?

The ruling was issued by the United States District Court for the District of Delaware.

What is treprostinil used for?

Treprostinil is used to treat pulmonary hypertension associated with interstitial lung disease.

ShareAdd on Google
Tags: UTHR United Therapeutics Liquidia treprostinil pulmonary hypertension patent litigation
Last updated: Sep 30, 2026

Biotech snapshot

Cash runway
$3803M liquidity · $0M/mo burn
Low dilution risk
Lead asset
GGTA1 KO ThymokidneyPhase 1
ESRD (End-Stage Renal Disease) →

Catalyst track record

+83%
best trade around UTHR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for UTHR.

See every catalyst's timing & PoA →